Project 7
HER2-positive advanced solid tumors
IND SubmittedUnder review
Key Facts
Indication
HER2-positive advanced solid tumors
Phase
IND Submitted
Status
Under review
Company
About Suzhou Teligene
Clinical-stage Chinese biotech developing brain-penetrant small molecule targeted therapies for oncology, with multiple programs in Phase I-II trials.
View full company profileTherapeutic Areas
Other HER2-positive advanced solid tumors Drugs
| Drug | Company | Phase |
|---|---|---|
| Project 3 | Suzhou Teligene | Phase I |